Prednisone and Cancer Risk: What You Need to Know

Prednisone sits in an unusual place in cancer medicine: it is both a treatment for certain cancers and a drug that, with prolonged use, may modestly raise the overall risk of developing cancer. A large South Korean population study found that long-term glucocorticoid users had about a 23% higher rate of new cancer diagnoses compared to unexposed individuals, with the strongest signals appearing in liver and lung cancer. But that single number conceals enormous variation by cancer type, dose, duration, and the reason the drug was prescribed in the first place. For anyone taking prednisone or weighing the risks of a long course, the reality is far more layered than a headline figure suggests.

How Prednisone Reshapes the Immune System’s Tumor Surveillance

Your immune system constantly patrols for abnormal cells, and a few cell types do most of the heavy lifting: cytotoxic T cells that kill tumor cells directly, natural killer cells that attack without needing prior exposure, and dendritic cells that present tumor fragments to rally the rest of the immune response. Prednisone and related glucocorticoids dial down nearly all of these simultaneously. They suppress the killing machinery of both T cells and natural killer cells, boost the activity of regulatory T cells (which act as brakes on the immune response), push immune-signaling macrophages toward states that actually support tumor growth, and expand a population of suppressor cells that further dampen immune vigilance.

A 2026 review in the Journal of Steroid Biochemistry and Molecular Biology described these combined effects as profoundly reshaping the tumor immune microenvironment, weakening surveillance in ways that could promote tumor progression, metastasis, and resistance to treatment.¹ In practical terms, this means that at high doses or over long periods, prednisone may create a more permissive environment for cancer cells that would otherwise have been caught early. A study in The Oncologist detailed the specific molecular changes: in natural killer cells, the protein that recognizes tumor targets gets turned down while a checkpoint brake (PD-1) gets turned up; in cytotoxic T cells, multiple checkpoint proteins increase while the signals that drive their killing function decrease.²

None of this means a short course of prednisone for a sinus infection will let cancer take hold. The immune changes are dose- and duration-dependent, and the body’s surveillance system has redundant layers. But for people on months or years of glucocorticoid therapy for conditions like autoimmune disease or organ transplant maintenance, the cumulative suppression of these defenses is real and measurable.

What Population Studies Actually Show About Long-Term Use

The most informative data comes from large cohort and case-control studies that track thousands of glucocorticoid users over years. The South Korean cohort study, which followed over 770,000 individuals, found that among about 1,600 long-term glucocorticoid users, the overall risk of a new cancer diagnosis was roughly 1.23 times that of unexposed people. The risk was not spread evenly: liver cancer risk was about 1.46 times higher and lung cancer risk about 1.52 times higher in the long-term users.³

Those numbers sound alarming, but context matters. A 1.23-fold increase means the absolute risk goes from roughly 4.7% to about 5.8% over the study period. That is a meaningful difference across hundreds of thousands of people, but for any individual, it is not the dramatic leap that “increased cancer risk” might imply. And some cancer types showed no association at all.

Colorectal cancer, for instance, appears unaffected. A study using data from Denmark found no link between frequent glucocorticoid use and colorectal cancer, even at high cumulative doses taken over more than five years.⁴ Early-onset basal cell carcinoma, the most common skin cancer, also showed no connection to systemic glucocorticoid use in a separate study.⁵ And a nationwide Danish study that examined melanoma risk specifically reported that corticosteroid use was not associated with melanoma, even though other immunosuppressive drugs (particularly those used in organ transplant recipients) were.⁶

The lymphoma question is particularly interesting because immune suppression is theoretically a strong driver of lymphoid cancers. Yet the population data here is reassuring. A Scandinavian case-control study of patients with giant cell arteritis and polymyalgia rheumatica, conditions treated with substantial cumulative steroid doses, found no increase in lymphoma risk. If anything, the odds ratio pointed slightly below 1.0, meaning steroid-treated patients were, if anything, slightly less likely to develop lymphoma than controls.⁷ A study in rheumatoid arthritis patients found a similar pattern: oral steroid treatment lasting more than two years was associated with a lower lymphoma risk, not a higher one.⁸

This may seem contradictory given the immune-suppression story. One possible explanation is that in autoimmune diseases, chronic inflammation itself drives lymphoma risk, and taming that inflammation with steroids offsets whatever immune-surveillance cost the drugs impose. It is a useful reminder that population-level cancer risk from prednisone is inseparable from the disease being treated.

Rare Lymphoproliferative Disorders and Individual Cases

Despite the reassuring population data on lymphoma, there are documented cases of what is called iatrogenic immunodeficiency-associated lymphoproliferative disorder, essentially abnormal lymphoid growths triggered by immunosuppressive therapy. A 2022 case report described a woman who developed such a disorder after five years of prednisolone treatment for autoimmune hemolytic anemia.⁹ This type of event is rare enough that it appears as individual case reports rather than in population studies, but it underscores that prolonged immunosuppression of any kind carries at least a theoretical risk of abnormal lymphoid proliferation. For most patients, this risk does not outweigh the benefit of treating a serious autoimmune condition, but it is something oncologists and rheumatologists keep in mind during long-term follow-up.

When Prednisone Is the Cancer Treatment

The relationship between prednisone and cancer is not purely adversarial. In blood cancers, glucocorticoids are therapeutic weapons. In acute lymphoblastic leukemia, the most common childhood cancer, glucocorticoids directly trigger programmed cell death in the malignant cells. The mechanism involves shifting the balance of pro- and anti-survival proteins inside leukemia cells, tipping the scales toward self-destruction.¹⁰ This cell-killing ability makes prednisone and related steroids a backbone of leukemia treatment protocols, particularly in the initial induction phase when the goal is to destroy as many cancer cells as quickly as possible.

Not all leukemia cells respond equally, though. Some develop resistance to glucocorticoid-induced death, which is a major problem because a patient’s early response to steroids is one of the strongest predictors of long-term survival. Research into overcoming this resistance has looked at combination approaches: one study found that adding a second compound could reactivate the cell-death pathway in glucocorticoid-resistant leukemia cells by amplifying the glucocorticoid receptor’s downstream signaling.¹¹

Prednisone also plays a different but critical role in metastatic prostate cancer. When given alongside abiraterone acetate, a drug that blocks androgen production, prednisone serves partly as hormone replacement, compensating for the cortisol drop that abiraterone causes, and partly as a modest anti-tumor agent in its own right.¹² A landmark trial published in the New England Journal of Medicine showed that adding abiraterone plus prednisone to standard treatment for men with metastatic prostate cancer significantly extended survival, with a 38% reduction in the risk of death compared to placebo.¹³ In these settings, the benefit of prednisone as part of the cancer treatment regimen vastly outweighs any incremental risk from the drug itself.

The Complication With Solid Tumors and Chemotherapy Resistance

In solid tumors like breast and cervical cancer, the glucocorticoid receptor tells a very different story than it does in leukemia. Rather than triggering cell death, glucocorticoid receptor activation in certain solid cancers appears to help tumor cells survive. A 2019 report in Cancer Discovery noted that glucocorticoid receptor activity increases at distant metastatic sites in breast cancer, suggesting the receptor may actually facilitate the spread of tumor cells to new locations.¹⁴

A similar concern has emerged with chemotherapy resistance. In cervical cancer, overexpression of the glucocorticoid receptor has been linked to poorer outcomes and resistance to cisplatin, a widely used chemotherapy drug.¹⁵ Research published in Nature Communications explored the mechanism behind this resistance and described it as a glucocorticoid receptor-centered pathway that protects solid tumor cells from platinum-based chemotherapy.¹⁶

This is a genuine clinical dilemma. Prednisone and dexamethasone are routinely given before chemotherapy to reduce nausea, swelling, and allergic reactions. For blood cancers, that co-administration is a bonus because the steroid is actively fighting the cancer too. For certain solid tumors, there is a growing suspicion that the same steroid might be protecting the very cancer cells the chemotherapy is trying to destroy. Oncologists are increasingly paying attention to this distinction, though practice guidelines have not yet broadly changed in response.

Prednisone and Immunotherapy: When Timing Is Everything

The explosion of immunotherapy, especially immune checkpoint inhibitors, has made the prednisone question more urgent. These drugs work by releasing the brakes on the immune system so it can recognize and attack tumors. Prednisone does the opposite: it puts those brakes back on. On paper, the two should be incompatible. The reality is more nuanced and depends heavily on timing and the reason the steroid is being used.

A 2024 systematic review in Cancer Medicine pooled data from multiple studies and found that when corticosteroids were given for reasons unrelated to the cancer itself, such as managing a pre-existing condition, they did not significantly reduce immunotherapy’s effectiveness. The pooled response rate was essentially identical between steroid users and non-users, and neither progression-free survival nor overall survival was meaningfully different.¹⁷

The picture changes when steroids are given specifically because the cancer is causing symptoms like brain swelling or breathing difficulty. In those cases, steroid use before immunotherapy, particularly at doses equivalent to 10 mg or more of prednisone per day, has been linked to poorer outcomes in melanoma and non-small cell lung cancer.¹⁸ But here is the tricky part: is that worse outcome because the steroid is blunting the immunotherapy, or because patients who need high-dose steroids before treatment tend to have more aggressive disease? Researchers have been grappling with this confounding factor for years, and the honest answer is that both explanations likely contribute.

When steroids are used after immunotherapy has started, specifically to manage immune-related side effects like colitis, hepatitis, or skin rashes caused by the treatment, the news is better. A 2025 study of non-small cell lung cancer patients found that using corticosteroids to manage these side effects did not erase the survival benefit of immunotherapy. Patients who developed immune-related adverse events and needed steroids to manage them still had dramatically better progression-free survival than patients who never had such events at all.¹⁹ A preclinical study in melanoma did provide a mechanistic caution, showing that prednisolone suppressed the T-cell activation that checkpoint inhibitors rely on, shifting the immune balance toward regulatory cells that protect the tumor.²⁰ So the underlying biology does support a dampening effect, but in practice, the benefit of controlling severe immune side effects appears to outweigh the immunological cost.

Inhaled Steroids and a Surprising Counterexample

Not all corticosteroid exposure carries the same implications. Inhaled corticosteroids, commonly used for asthma and chronic obstructive pulmonary disease, deliver the drug directly to the lungs at much lower systemic doses than oral prednisone. A study of COPD patients found that high-dose inhaled corticosteroids were actually associated with a substantially lower risk of lung cancer compared to non-users, with the protective effect appearing to strengthen at higher inhaled doses.²¹ This is essentially the opposite of what the South Korean cohort found for systemic glucocorticoid use and lung cancer.

The likely explanation is that COPD involves chronic inflammation in the airways, and that inflammation itself is a driver of lung cancer. Delivering anti-inflammatory steroids directly to the site of inflammation may interrupt that process without causing the systemic immune suppression that oral prednisone does. The finding reinforces a recurring theme: whether corticosteroids raise or lower cancer risk depends entirely on the type of exposure, the tissue involved, and the underlying disease.

Practical Considerations for People Taking Prednisone

If you are on a short course of prednisone for an acute problem, like an asthma flare, a poison ivy reaction, or a temporary autoimmune episode lasting a few weeks, the evidence does not suggest you should worry about cancer risk from the drug. The population studies that found increased cancer risk specifically identified long-term users, generally defined as cumulative use over months to years.

If you are on long-term prednisone for a chronic condition and cannot easily stop, the absolute increase in cancer risk remains small for most cancer types, and several common cancers show no association at all. The practical move is not to panic but to keep up with age-appropriate cancer screening and to work with your doctor on using the lowest effective dose. Steroid-sparing strategies, where other drugs are added so the prednisone dose can be reduced, exist for many autoimmune and inflammatory conditions and are worth discussing.

For people already undergoing cancer treatment, the relationship with prednisone depends on the type of cancer and the type of therapy. In blood cancers and prostate cancer, prednisone is often part of the treatment itself. If you are on immunotherapy for a solid tumor, your oncologist is likely already thinking carefully about when and whether to use corticosteroids. The most important thing you can do is be transparent about any steroid use, including prescriptions from other doctors, so your cancer care team can factor it into treatment decisions. The difference between a steroid given for a pre-existing condition and one given because the cancer is causing urgent symptoms can change how your oncologist interprets your response to treatment.